TrialActa dermato-venereologica2023

Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks.

Elke L M Ter Haar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.